Zytorvi 240mg Injection contains the active ingredient Toripalimab. It is a monoclonal antibody used in the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). It is administered as a first-line therapy in combination with cisplatin and gemcitabine for adult patients and as a single agent for those with recurrent, unresectable, or metastatic NPC that has progressed after platinum-based chemotherapy. 

Zytorvi 240mg Injection works by blocking the PD-1 receptor, preventing its interaction with the PD-L1 and PD-L2 ligands. This action lifts the inhibition on T cells, boosting their activity and enhancing immune surveillance, ultimately promoting an anti-tumor immune response. In preclinical models, PD-1 blockade demonstrated a reduction in tumor growth.

Zytorvi 240mg Injection is associated with common side effects, including nausea and vomiting, burning or tingling sensations in the feet and toes, decreased appetite, diarrhea, and constipation. It carries warnings for severe immune-mediated adverse reactions, which may affect any organ or tissue and could be fatal. These reactions can occur at any time during treatment or even after discontinuation, requiring close monitoring and immediate medical intervention when necessary. 

Also, infusion-related reactions such as hypersensitivity and anaphylaxis may occur during administration. For patients who have undergone or are undergoing allogeneic hematopoietic stem cell transplantation (HSCT), Zytorvi 240mg Injection may lead to serious complications such as graft-versus-host disease (GVHD) and other transplant-related issues. Zytorvi 240mg Injection is contraindicated during pregnancy due to the risk of fetal harm, including potential fetal death.

First-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine.

Single-agent treatment for adults with recurrent, unresectable, or metastatic NPC that has progressed after platinum-containing chemotherapy.

Zytorvi 240mg Injection blocks the PD-1 receptor, preventing its interaction with the PD-L1 and PD-L2 ligands. This action stimulates T cells, enhancing their activity and restoring immune surveillance to promote an anti-tumor immune response. In preclinical models, blocking PD-1 activity reduced tumor growth.

Your healthcare provider administers Zytorvi 240mg Injection through an intravenous (IV) line into your vein over 30 to 60 minutes. It is usually given every two or three weeks as an IV infusion. Your healthcare provider will decide the number of treatments you need and monitor your blood for potential side effects. If you miss an appointment, contact your healthcare provider immediately to reschedule.

Decreased appetite

Nausea and vomiting

Constipation and diarrhoea

Muscle and bone pain

Dizziness

Burning or feeling of pins and needles in feet and toes

Upper respiratory infection

Sleep problems

Rash

Fever and cough

Low levels of thyroid hormone

Severe allergic reactions such as difficulty breathing, swelling of face or throat

Liver problems (e.g., yellowing of skin or eyes, dark urine)

Lung problems (e.g., shortness of breath, cough, chest pain)

Immune system problems leading to inflammation in organs

Endocrine problems

Severe infections

It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Zytorvi 240mg Injection, potentially affecting their effectiveness or causing side effects.

Store in the original packaging to protect from moisture.

Avoid direct sunlight

Store Zytorvi 240mg Injection in a refrigerator at a temperature of 2°C to 8°C.

Do not freeze or shake it.

Keep out of reach of children and pets.

Zytorvi 240mg Injection can cause severe and potentially fatal immune-mediated reactions, which may affect any organ and occur at any time during treatment or after discontinuation, requiring close monitoring. It may also cause infusion-related reactions, including severe hypersensitivity or anaphylaxis. Patients undergoing or planning HSCT should be aware of potential complications like graft-versus-host disease. Additionally, Zytorvi 240mg Injection can harm a developing fetus, so it should be avoided during pregnancy. Always follow your healthcare provider’s instructions and attend regular check-ups to manage any risks.